Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
Aurora
13123 East 16th Ave Aurora, CO 80045

720-777-1234

Stanley Szefler, MD

Allergy and Immunology

Board Certified

Locations

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
Aurora
13123 East 16th Ave, Aurora, CO 80045

720-777-1234

Provider Expertise

Clinical Interest for Patients

I am interested in Childhood asthma; Asthma pharmacotherapy; Inhaled corticosteroids; Biomarkers; Predictors of treatment response and Monitoring treatment response; School-centered asthma programs.


Specialties

  • Pediatrics
  • Allergy and Immunology

Conditions & Treatments

  • Immune System

    Allergies

  • Lungs and Breathing

    Asthma

Education & Training

Medical Schools

MD, State University of New York - Buffalo (1975)


Undergraduate Schools

BSc, State University of New York at Buffalo (NY) (1971)


Internships

University at Buffalo School of Medicine Program (1976)


Residency Program

University at Buffalo School of Medicine Program (1977)


Fellowships

Women and Children's Hospital of Buffalo/University at Buffalo Program (1979)

Professional Memberships

American Academy of Allergy Asthma and Immunology , Member


American Academy of Pediatrics (AAP), Member


American College of Allergy, Asthma and Immunology , Member


American Society of Pharmacology and Experimental Therapeutics , Member


American Thoracic Society (ATS), Member


Colorado Allergy Society , Member


Colorado Trudeau Society/Medical Section of the American Lung Association of Colorado , Member


Society of Pediatric Research , Member


Research & Grants

Grants

Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) (2017)

Colorado Comprehensive School-centered Asthma Program (AsthmaCOMP) (2018)

Reducing Asthma Attacks in Disadvantaged School Children with Asthma (2020)


Research Interests for Patients

Dr. Szefler's major contributions are directed toward the appropriate use of long-term control therapy in asthma, including the recognition of variability in response to asthma therapy. He has identified biomarkers and asthma characteristics that can be used to predict and thus individualize asthma therapy. Dr. Szefler is the Director of the Pediatric Asthma Research Program and Research Medical Director in the Breathing Institute of the Pediatric Pulmonary Section at Children's Hospital Colorado. He is also Professor of Pediatrics at the University of Colorado Denver School of Medicine. He is also a former member of the Expert Panel for the National Heart, Lung, and Blood Institute's National Asthma Education and Prevention Program on "Guidelines for the Diagnosis and Management of Asthma" and a former member of the Global Initiative for Asthma Science Committee. From 1997 through 2018 he served as Deputy Editor for the Journal of Allergy and Clinical Immunology. He has published more than 600 scientific articles and co-edited books on severe asthma, childhood asthma and pediatric allergy and immunology and personalized medicine. He is the Co-Principal Investigator for the NHLBI PrecISE Network that is focused on identifying new treatment for severe and exacerbation prone asthma. He is the Co-Principal Investigator for the NHLBI DECIPHeR Alliance that is designed to reduce health disparities by improving asthma control in disadvantaged children. For the past fifteen years, he has directed a school-based asthma program for the Denver Public School system funded by the Colorado Department of Public Health and Environment Colorado Cancer, Cardiovascular and Pulmonary Disease Program. This program seeks to define the prevalence and severity of asthma, identify those most significantly affected, and to direct those children to state of the art asthma care. The program was recently awarded a NHLBI UG3 dissemination and implementation grant (DECIPHeR) to assess the feasibility of extending the school-centered asthma program to 5 regional hubs in Colorado.

information for referring providers

Referral Contact Phone

(720) 777-6181

Clinical Interests for Referring Providers

I am interested in Childhood asthma; Asthma pharmacotherapy; Inhaled corticosteroids; Biomarkers; Predictors of treatment response and Monitoring treatment response; School-Centered asthma programs.

Research Interest for Referring Providers

Dr. Szefler’s major contributions are directed toward the appropriate use of long-term control therapy in asthma, including the recognition of variability in response to asthma therapy. He has identified biomarkers and asthma characteristics that can be used to predict and thus individualize asthma therapy. Dr. Szefler is the Director of the Pediatric Asthma Research Program and Research Medical Director in the Breathing Institute of the Pediatric Pulmonary and Sleep Medicine Section and Interim Medical Director for the Research Institute at Children’s Hospital Colorado. He is also Professor of Pediatrics with Tenure at the University of Colorado Denver School of Medicine. He is a former member of the Expert Panel for the National Heart, Lung, and Blood Institute’s National Asthma Education and Prevention Program on “Guidelines for the Diagnosis and Management of Asthma” and a former member of the Global Initiative for Asthma Science Committee. From 1997 through 1998, he was a Deputy Editor for the Journal of Allergy and Clinical Immunology. He has published more than 600 scientific articles and co-edited books on severe asthma, childhood asthma, pediatric allergy and immunology and personalized asthma management for clinicians. He is the Co-Principal Investigator for the NHLBI DECIPHeR Alliance that is designed to reduce health disparities by improving asthma control in disadvantaged children. For the past fifteen years, he has directed a school-based asthma program for the Denver Public School system funded by the Colorado Department of Public Health and Environment Colorado Cancer, Cardiovascular and Pulmonary Disease Program. This program seeks to define the prevalence and severity of asthma, identify those most significantly affected, and to direct those children to state of the art asthma care. This program also developed a mentorship program for school nurses and was supported by Glaxo Smith Kline in order to set a national standard for school-based asthma management. The program was recently awarded a NHLBI UG3 dissemination and implementation grant (DECIPHeR) to assess the feasibility of extending the school-centered asthma program to 5 regional hubs in Colorado.